Roche Reports Acceptance of BLA for Fixed-Dose SC Combination of Perjeta and Herceptin to Treat HER2-Positive Breast Cancer

Roche Reports Acceptance of BLA for Fixed-Dose SC Combination of Perjeta and Herceptin to Treat HER2-Positive Breast Cancer

Roche Reports Acceptance of BLA for Fixed-Dose SC Combination of Perjeta and Herceptin to Treat HER2-Positive Breast Cancer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post